March Biosciences is a clinical-stage biotechnology company developing MB-105, a first-in-class CD5-targeted CAR T-cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma. These patients have limited options after failing first line standard of care therapy, and face a poor prognosis with 3-year survival rates ranging from 10–20%, depending on disease subtype. MB-105 uses a proprietary CAR construct to selectively eliminate malignant CD5-positive cells while preserving key healthy T-cell populations. In a Phase 1 clinical trial, administration of MB-105 led to multiple long term and durable complete responses and showed a favorable safety profile with limited CAR-associated toxicities. Based on these encouraging results, March initiated a multi-center Phase 2 trial in early 2025, which has begun dosing patients and aims to enroll approximately 46 patients across the United States.
Recent News
March Biosciences: Interview With Co-Founder & CEO Sarah Hein About The Cell Therapy Company (5-9-25)
Houston cell therapy company launches second-phase clinical trial (5-7-25)
ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy (4-29-25)
MILESTONESSeries A |
TARGET CANCERSHemotological Cancers (Lymphoma and Leukemia) |
FOCUS SECTORTherapeutics |
WHY WE INVESTED
We invested in March Biosciences due to its potential to address a critical unmet need in the treatment of T-cell lymphomas. Our due diligence team, with deep expertise in CAR T-cell therapies, was particularly encouraged by the company’s novel approach to targeting malignant cells while limiting impact on healthy T-cells. Early clinical data reinforced confidence in the therapy’s safety and potential effectiveness.
In addition, the company’s recent funding round, which attracted strong interest from leading institutional investors, offered our community a rare opportunity to participate in a highly competitive raise.